GPCRs: emerging targets for novel T cell immune checkpoint therapy
Cancer Immunology, Immunotherapy · 03.10.2024 · 73 (12)
DOI: 10.1007/s00262-024-03801-7 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancer Immunology, Immunotherapy, online erschienen am 03.10.2024. Verfasst von Kaitlyn Dickinson und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Division of Surgical Oncology, University of Colorado Anschutz Medical Campus, Aurora, CO, USA. Hauptthemen laut MEDLINE: Receptors, G-Protein-Coupled, Neoplasms. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 167 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS, NIH HHS, NIH T32 Training Grant in Cancer Immunotherapy and Experimental Therapeutics.
Abstract (Originalsprache)
Although immune checkpoint blockade (ICB) has become the mainstay of treatment for advanced solid organ malignancies, success in revitalizing the host anticancer immune response remains limited. G-protein coupled receptors (GPCRs) are a broad family of cell-surface proteins that have been regarded as main players in regulating the immune system, namely by mediating the activity of T lymphocytes. Among the most novel immunoregulatory GPCRs include GPR171, lysophosphatidic acid receptors (LPARs), GPR68, cannabinoid receptor 2 (CB2), and prostaglandin E receptors, many of which have shown promise in mediating antitumor response via activation of cytotoxic T cells, inhibiting immunosuppressive lymphocytes, and facilitating immune cell infiltration within the tumor microenvironment across multiple types of cancers. This paper reviews our current understanding of some of the most novel GPCRs-their expression patterns, evolving roles within the immune system and cancer, potential therapeutic applications, and perspective for future investigation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Surgery, Division of Surgical Oncology, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
- Department of Surgery, Division of Surgical Oncology, University of Colorado Anschutz Medical Campus, Aurora, CO, USA. yuwen.zhu@cuanschutz.edu.
Förderung
- NCI NIH HHS
- NIH HHS
- NIH T32 Training Grant in Cancer Immunotherapy and Experimental Therapeutics
- Wings of Hope for Pancreatic Research
- National Institutes of Health
Zitieren
APA
Dickinson, K., Yee, E. J., Vigil, I., Schulick, R. D., & Zhu, Y. (2024). GPCRs: emerging targets for novel T cell immune checkpoint therapy. Cancer Immunology, Immunotherapy, 73(12). https://doi.org/10.1007/s00262-024-03801-7
Vancouver
Dickinson K, Yee EJ, Vigil I, Schulick RD, Zhu Y. GPCRs: emerging targets for novel T cell immune checkpoint therapy. Cancer Immunology, Immunotherapy. 2024;73(12). doi:10.1007/s00262-024-03801-7
BibTeX
@article{Dickinson2024,
author = {Dickinson, Kaitlyn and Yee, Elliott J and Vigil, Isaac and Schulick, Richard D and Zhu, Yuwen},
title = {GPCRs: emerging targets for novel T cell immune checkpoint therapy},
journal = {Cancer Immunology, Immunotherapy},
year = {2024},
volume = {73},
number = {12},
doi = {10.1007/s00262-024-03801-7}
}
EUVIMED